April 16th 2024
The 3 new additional studies are the ABLE-22, ABLE-32, and ABLE-42 clinical trials.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Enfortumab granted breakthrough therapy designation for metastatic urothelial Ca
March 18th 2020The FDA has granted Breakthrough Therapy designation for enfortumab vedotin-ejfv (PADCEV) in combination with the anti-PD-1 therapy pembrolizumab (KEYTRUDA) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.
Long-term QoL data support adding chemo to RT for localized MIBC
February 17th 2020“Our study showed that at least with the regimen used in our trial, patients can have chemotherapy in addition to radiotherapy without any fear that it will impair their quality of life,” says researcher Robert A. Huddart, MD, PhD.
Investigational urothelial Ca Tx undergoing priority review by FDA
February 17th 2020“In the OLYMPUS trial, more than half of patients receiving the gel had complete regression of their cancers, and most of the responses were durable. Based on these results, if UGN-101 is approved, it can be strongly considered as a kidney-sparing option for a challenging cancer," says John L. Gore, MD, MS.
Bladder cancer biomarker test accurately adjudicates atypical cytology
February 5th 2020“The results of our retrospective study support taking advantage of the Cxbladder test to identify patients who should be further evaluated for cancer and to spare those who likely do not have cancer from an unnecessary workup," says Badrinath Konety, MD, MBA.
Bladder Ca: Genetic testing, targeted therapies signal a new era of precision medicine
February 5th 2020“We’re in an era of more personalized or precision medicine, and the ability to target cancer treatment to a patient’s specific genetic mutation or biomarker is becoming the standard,” according to Richard Pazdur, MD.
Pembrolizumab granted new bladder Ca indication
January 14th 2020The FDA has approved the anti-PD-1 therapy pembrolizumab (KEYTRUDA) as monotherapy for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk, nonmuscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
FDA approves enfortumab for locally advanced or metastatic urothelial Ca
January 14th 2020The FDA has granted accelerated approval to enfortumab vedotin-ejfv (PADCEV) for the treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and a platinum-containing chemotherapy before or after surgery or in a locally advanced or metastatic setting.
Worse perioperative outcomes seen in bladder Ca patients ≥80 years
December 2nd 2019A study investigating discharge destination and perioperative complications after radical cystectomy provides useful data for risk stratification and preoperative counseling of patients 80 years of age and older, said Hayden M. Hill, MD, who presented the research at the American College of Surgeons Clinical Congress in San Francisco.
Survival rates appear comparable for robotic, open cystectomy
November 4th 2019"It’s critically important to not overemphasize the benefits or overlook the concerns related to new technology or surgical approaches as is too often the case in the marketing campaigns by various centers (both academic and community)," writes Badar M. Mian, MD.
Tecentriq plus chemotherapy extends progression-free survival
October 29th 2019Adding immunotherapy in the form of atezolizumab (Tecentriq) to platinum-based chemotherapy extends progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic urothelial carcinoma, according to results from a phase III study.
How has FDA label change affected treatment of advanced bladder Ca?
October 23rd 2019Access to novel therapies early in the regulatory process as a result of the FDA’s accelerated approval program can be valuable for many cancer patients, but the clinicians who are responsible for their care must have heightened vigilance for incoming data and FDA guidance about these drugs that have not gone through the “gold standard” of phase III testing.
Cystoscopy overuse common in surveillance of low-risk bladder Ca
September 9th 2019Despite recommendations for low-intensity cystoscopic surveillance in low-risk non-muscle invasive bladder cancer patients, U.S. Department of Veterans Affairs providers overused cystoscopy in 75% of these patients, according to a study published in Urology (2019; 131:112-9).
Hematuria evaluation approaches compared
August 19th 2019“The variability in recommendations [for hematuria evaluation] and our study’s findings highlight implicit value judgments and a potentially high burden of harms not historically considered in many guidelines’ development process," says Matthew E. Nielsen, MD, MS.
PD-L1 inhibitor plus chemo improves PFS for metastatic urothelial Ca
August 19th 2019Treatment combining the immunotherapy atezolizumab (Tecentriq) and platinum-based chemotherapy significantly improved progression-free survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma compared to chemotherapy alone.
Novel urothelial cancer Tx shows impressive response in phase II trial
July 15th 2019The novel antibody-drug conjugate enfortumab vedotin produced an impressive 44% response rate in a phase II trial of urothelial cancer patients who had been treated with standard chemotherapy and a checkpoint inhibitor.
Sense of urgency surrounds BCG shortage
June 12th 2019As urologists maneuver through the third shortage of bacillus Calmette-Guérin during the past decade, there is a sense of urgency to find short- and long-term alternative treatments to the only FDA-approved BCG strain as a therapeutic agent for nonmuscle-invasive bladder cancer.
Novel immunotherapy promising in BCG-unresponsive NMIBC
June 10th 2019The combination of an IL-15 cytokine agonist known as N-803 and bacillus Calmette–Guérin (BCG) was well tolerated and offered promising activity in patients with nonmuscle-invasive bladder cancer (NMIBC) who did not respond to BCG therapy, according to phase I and II study results.